Mumps virus (MuV) is a negative-sense, single-stranded RNA virus belonging to the family Paramyxoviridae. MuV causes mumps, a communicable human disease that is generally mild and self-limiting, characterized by pain and swelling of the parotid gland(s). Humans are the only known reservoir for MuV. As there is currently no animal model (Carbone & Rubin, 2007) in vivo knowledge of the virus is limited. Experimental data on MuV has been obtained from previous in vivo studies; however, results have been inconclusive or experiments not designed in a manner in which results could be translated into human disease. MuV studies have been previously performed using rhesus macaque (Johnson & Goodpasture, 1934) , cat (Enders et al., 1945; Wollstein, 1916) , guinea pig (Enders et al., 1945; Tokuda, 1957; van der Veen & Sonderkamp, 1965) , hamster (Ferm & Kilham, 1963; Houard et al., 1995) and mouse (Overman, 1954; Tsurudome et al., 1987) models. An effective animal model would be of great use for studying pathogenesis, virulence, tissue tropism and persistence of MuV. It could also be useful for assessing attenuated vaccines.
MuV and influenza share some biological properties, and until the 1950s, were classified as members of the same virus family (Andrewes et al., 1955) . Both are negativesense, single-stranded RNA viruses which utilize sialic acid as their cellular receptor and have proteins with haemagglutinin and neuraminidase activities. Ferrets are established as a successful animal model for studying influenza virus infection (Maher & DeStefano, 2004; Matsuoka et al., 2009) and provide an accurate representation of human influenza infection. We hypothesized that ferrets may also be a suitable model for studying MuV infection.
Early experiments reported that ferrets inoculated with MuV by intratesticular injection showed no signs of illness or serum antibody response (Enders et al., 1945) . However, ferrets infected intranasally with an egg-adapted MuV strain were shown to elicit a serum antibody response and the infection resulted in bronchiolitis. Infectious virus was recovered from nasal washings, turbinates and lungs at days 3 and 4 post-infection (Gordon et al., 1956) . Ferrets have also been employed successfully in studies on measles virus, a related paramyxovirus, using canine distemper virus (CDV) as a model organism (Kauffman et al., 1982; Mehta & Thormar, 1979) . It has been suggested that they may be valuable for assessing attenuated paramyxovirus vaccine candidates (Nguyen et al., 2012 ). Here we demonstrate that ferrets produce a mumps infectionspecific serum antibody response and a cytokine response consistent with infection, detectable in PBMCs.
Clinical MuV AFZ315 was a saliva sample taken from a patient two days after the onset of parotitis and attenuated vaccine strain RIT4385 was used directly from monovalent vaccine bulk. Clinical MuV NIBSC1.1/P1V was isolated from a nose and throat swab by one passage on Vero (African Green Monkey kidney) cells. The influenza A PR/8 virus used was a high growth laboratory strain. All viruses were obtained from archived material held at the National Institute for Biological Standards and Control (NIBSC) and were titrated by plaque assay on Vero cells (Afzal et al., 2005) .
Two groups of three male ferrets aged between 8 and 12 months were inoculated intranasally with either 7610 shedding and blood was sampled every seven days over a 28 day period. Animals were killed humanely on day 28 and 20 % homogenates of tissues prepared in Minimum Essential Medium supplemented with 4 % FCS, 2 % Lglutamine, 2 % penicillin-streptomycin, 2 % amphotericin B and 0.5 % gentamicin. Sera were separated from red blood cells in Serum Clot Activator tubes (Sarstedt) and used in plaque reduction neutralization (PRN) assays as previously described (Cohen et al., 2007) to determine if the ferrets generated a serum antibody response to MuV. RNA was extracted from clinical samples and tissue homogenates using Trizol LS (Life Technologies). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and MuV small hydrophobic (SH) genes were amplified by real-time reverse transcription PCR (RT-PCR) using the Qiagen QuantiTect Probe RT-PCR kit and ABI 7900HT Fast real-time PCR system using SDS v2.4 software (Life Technologies). The methods detailed here were used in all studies and apply throughout unless stated otherwise. Primer and probe sequences are detailed in Table S1 (available in JGV Online).
Ferrets exhibited no clinical signs of disease, such as swelling of testes or head and neck areas. No MuV RNA was recovered from clinical samples or tissue homogenates (parotid gland, testes, lymph node, tonsil, turbinates, lung, spleen, brain, kidney, heart, liver, tongue, pancreas, colon, salivary gland, adrenal gland and small intestine). In order to determine the sensitivity limit of our detection method, we spiked either 20 % homogenates of uninfected ferret brain, spleen and kidney or MEM with known quantities (p.f.u.) of clinical MuV AFZ315 and compared them by real-time RT-PCR. The limit of detection was calculated to be approximately 6000 p.f.u. per gram of ferret (data not shown).
PRN assays demonstrated that ferrets inoculated with clinical (AFZ315) and vaccine (RIT4385) MuVs elicited a neutralizing antibody (NAb) response by day 28 as demonstrated by statistically significant increases in the 50 % end-point titres (neutralizing dose, ND 50 ) compared to the pre-infection values ( Fig. 1a-f ). Ferrets 1, 4 and 6 showed a clear rise in titre at day 28 with ND 50 values of 42, 30 and 40, respectively (unpaired two-tailed t-test P-values of 0.0002, 0.0007 and ,0.0001, respectively). In addition, ferret 4 demonstrated an increase between days 21 and 28. While the increase in ND 50 values at day 28 for ferrets 2, 3 and 5 was not as remarkable (yielding values of 12, 16 and 14, respectively) the values were, nevertheless, statistically significant (P50.0052, ,0.001 and 0.0004).
In order to assess if the NAb response was mumpsinfection-specific, three ferrets were inoculated intranasally with 2610 4 p.f.u. per ferret of heat-inactivated RIT4385 (Chu & Morgan, 1950) . Blood was sampled every seven days and sera obtained as previously described. PRN assays were performed and the data obtained were compared against those for live RIT4385 (Fig. 1d-f) . Ferrets B and C showed a small increase over a 28 day period with maximum ND 50 titres of 10.5 and 10, respectively, although ferret A demonstrated a rise in titre at days 28 to 16 (Fig. 2a-c) , giving similar results to ferrets 3 and 5 in Fig. 1 . Unpaired two-tail t-tests comparing the preinfection and day 28 data from each animal showed that these differences were not statistically significant (P50.0640, 0.5126 and 0.2711). In these experiments, the NAb response induced by live RIT4385 was greater than that induced by heat-inactivated RIT4385 in two out of three ferrets. The data suggest that the ferrets exposed to live virus had been infected and that the NAb response exhibited by the ferrets was specific to MuV infection.
To investigate NAb specificity further, PRN assays were performed using day 28 sera from ferrets inoculated with AFZ315 ( Fig. 1a-c) or RIT4385 (Fig. 1d-f ) MuVs, and challenged with either clinical MuV isolate NIBSC1.1/P1V or influenza A PR/8. Results were not entirely consistent with the data from Fig. 1 in that serum from ferret 1 would have been expected to have a higher ND 50 titre than serum from ferret 2 when challenged with NIBSC1.1/P1V and this was not the case. Sera from ferrets 2 and 6 generated the highest titres of 41 and 50, respectively (Fig. 2d) . Fig. 2 (e) demonstrates that day 28 sera from ferrets 3, 4, 5 and 6 are not capable of effectively neutralizing PR/8; however, ferrets 1 and 2 gave ND 50 values of 11 and 14, respectively, similar to Fig. 1 .
We hypothesized that MuV was not detected in day 28 tissue homogenates due to the NAb response clearing the virus from the animals at this time point. To investigate this, eight ferrets were inoculated intranasally with 7610 3 p.f.u./ferret of clinical AFZ315. Two animals were killed humanely on days 1, 4, 7 and 14 post-infection and tissue homogenates prepared as previously described. PBMCs were isolated from terminal bleeds using Ficoll Paque Plus (GE Healthcare). MuV RNA was not detected by real-time RT-PCR in any tissue homogenates or PBMCs. In order to directly assess whether the ferrets had been exposed to a pathogen, the Qiagen QuantiTect SYBR Green real-time RT-PCR kit was used for detection of IFN-c, IL-2, IL-6 and IL-10 mRNA in PBMCs. The fold change in mRNA levels between pre-infection and test bleeds were calculated using fold mRNA change52 -DDCt (Svitek & von Messling, 2007) . IFN-c mRNA levels showed a mean fold increase of 2.0 on day 14 post-infection (Fig. 3a) . IL-2, IL-6 and IL-10 mRNA levels peaked on day 4 post-infection (mean fold increases of 20, 2610 4 and 600, respectively) Fig. 3(b-d) .
These data suggested that the ferrets had been exposed to virus and we proposed that lack of recoverable virus from tissue homogenates may have been due to a low inoculum titre. To test this, six ferrets were inoculated intranasally with MuV AFZ315 that had been propagated in primary human airway epithelial cells, thereby increasing virus inoculum titre from 7610 3 to 1610 5 p.f.u./ferret. Two animals were killed humanely on days 4, 7 and 14 postinfection and 20 % tissue homogenates prepared. No MuV RNA was detected by real-time RT-PCR, suggesting that a higher titre of inoculum does not increase the likelihood of recovering viral RNA from ferret tissues.
The observation of increased levels of IFN-c and cytokine mRNA in PBMCs is consistent with viral infection. Furthermore, the ferrets elicited a serum antibody response after inoculation with clinical or attenuated vaccine MuV, suggesting they had been infected. No animals in these studies exhibited clinical signs of illness. While such signs would be of benefit to a model, guinea pigs have been shown to be an efficient model for studying influenza virus infection and transmission in the absence of clinical signs (Lowen et al., 2006) . Although MuV is widely regarded to be serologically monotypic (Rubin et al., 2006) , data on immune responses to mumps are lacking and there is currently no known correlate of protective immunity. It is possible that antibodies raised against one MuV strain will be capable of providing protection against all mumps strains, but to different levels dependent upon the infecting strain. This has previously been demonstrated in mumps PRN assays (Pipkin et al., 1999) and may provide an explanation for the results described in Fig. 2 in which sera from ferrets did not produce consistent ND 50 titres when challenged with different MuVs. However the ferret NAbs did successfully neutralize RIT4385 (genotype A), AFZ315 (genotype J) and NIBSC1.1/P1V (genotype G).
Increases in mRNA levels of IL-2, IL-6 and IL-10 (by day 4) and IFN-c (by day 14) in PBMCs from ferrets infected with clinical MuV is consistent with previous studies in which concentrations of these cytokines were found to be elevated in mumps meningitis patients (Ichiyama et al., 2005) . mRNA levels of IFN-c, IL-2, IL-6 and IL-10 in PBMCs from ferrets infected with non-lethal CDV have been reported to increase at days 3 or 7 post-infection (Svitek & von Messling, 2007) , and these elevations are consistent with innate (IL-6), T-helper cell 1 (Th1) (IFN-c and IL-2) and T-helper cell 2 (Th2) (IL-10) types of immune responses, suggesting that this may also be the case in ferrets after infection with clinical MuV. However, as there was no overt correlative viraemia other than production of NAbs it is difficult to use these results conclusively.
Wild-type MuVs spread in saliva or respiratory droplets, and oral swabs are a common means of obtaining a clinical sample; therefore it was expected that clinical MuV would be detected in oral fluid or nasal washes. The fact that no attenuated vaccine virus was recovered was less concerning as there is no reported connection between RIT4385 and virus shedding, and its attenuation may account for reduced or lack of replication in tissues. Increasing viral input titre from 7610 3 to 1610 5 p.f.u./ferret did not yield virus from tissue homogenates; therefore it was concluded that a low inoculum titre was likely not to be the reason for this. Our data were in contrast to a previous study in which infectious MuV was recovered from ferret nasal washings, lung and turbinate samples (Gordon et al., 1956) ; however, the virus used in that study was adapted by allantoic passage in embryonated hen eggs and we used an unpassaged clinical sample.
The limit of detection was calculated to be approximately 6000 p.f.u. per gram of ferret. This is a large quantity of virus, so we assumed that the inoculum MuV would need to be concentrated in one or two tissues or be replicating efficiently in order to be detected by the method used here. The sensitivity limit of the real-time RT-PCR assay may provide one explanation as to why no clinical MuV RNA was detected, although it may be that the virus has a restricted tropism in ferrets. The animals' antiviral response may have played a role in inhibiting MuV replication. IFN-c has been reported to act in a tissuedependent manner during clearance of vaccinia and alphaviruses (Binder & Griffin, 2001; Kündig et al., 1993) . It upregulates several antiviral genes including dsRNAspecific adenosine deaminase (ADAR) which may cause the translation of non-functional proteins (Patterson et al., 1995) , and protein kinase dsRNA-regulated (PKR) which can activate NF-kB (Zamanian-Daryoush et al., 2000) . The MuV V protein may also not be fully functional in ferret cells and tissues, and could play a role in determining host range as has been described for the V protein of RSV (Bossert & Conzelmann, 2002) and NDV (Park et al., 2003) .
The in vivo study presented here provides evidence of immunogenicity in ferrets specific to MuV infection after intranasal inoculation and reports for the first time on cytokine production in an animal model after MuV infection. These results alone are not conclusive as to whether or not the ferrets were infected with MuV, and infection of ex vivo ferret airway cells would be useful to confirm if ferret cells are capable of being infected with 
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MuV. No live virus or viral RNA was recovered from any nasal washes, urine, faeces, PBMCs or tissues, indicating that the virus was not shedding from the animals and that it is unlikely that it was replicating to significant levels in tissues. If virus is not being shed, transmission studies are not possible, and a lack of clinical symptoms and recovery of virus from samples make fundamental in vivo mumps research and the investigation of attenuated vaccine viruses using this model difficult. These data do not exclude the ferret as a suitable model for MuV, but more information is required on the appropriate inoculum and dose and possible bio-distribution in the ferret that may explain the variation in immune response and absence of clinical signs. 
